IGIV Trials Should Focus On Infections, Use Non-Inferiority Design - FDA
Executive Summary
Clinical trials for intravenous immune globulin products can be "non-inferiority" studies, Center for Biologics Evaluation & Research Hematology Division Deputy Director Basil Golding, MD, told the Blood Products Advisory Committee.
You may also be interested in...
FDA To “Revisit” Intravenous Immune Globulin Clinical Trial Design
FDA will revisit its intravenous immune globulin Phase III clinical trial design recommendations in light of decreased adverse event rates for the therapies
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011